NEW YORK, January 27, 2017 /PRNewswire/ --
Stock-Callers.com today presents the following equities for evaluation:Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Ocular Therapeutix Inc. (NASDAQ: OCUL), Radius Health Inc. (NASDAQ: RDUS), and Grifols S.A. (NASDAQ: GRFS). According to financial services firm Raymond James, the iShares NASDAQ Biotechnology Index ETF gained
On Thursday, shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. recorded a trading volume of 685,755 shares, and ended the session 4.08% lower at $1.41. The stock is trading 13.39% below its 50-day moving average. Shares of the Company, which focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the US, have a Relative Strength Index (RSI) of 34.72. Your complete research report on IDRA can be retrieved for free at:
Bedford, Massachusetts headquartered Ocular Therapeutix Inc.'s stock closed the day 2.02% lower at $6.79. A total volume of 1.47 million shares was traded, which was above their three months average volume of 949,890 shares. The Company's shares have advanced 4.30% in the previous three months. The stock is trading 12.92% below its 200-day moving average. Additionally, shares of Ocular Therapeutix, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, have an RSI of 25.72.
On January 24th, 2017, Ocular Therapeutix announced the pricing of a registered underwritten public offering of 3,571,429 shares of its common stock at a public offering price of $7.00 per share. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about January 27th, 2017, subject to customary closing conditions. A free report on OCUL is just a click away at:
Shares in Waltham, Massachusetts headquartered Radius Health Inc. recorded a trading volume of 520,416 shares, and ended yesterday's trading session 0.43% higher at $42.05. The stock has advanced 5.76% in the past month and 10.57% on an YTD basis. The Company's shares are trading below their 200-day moving average by 6.08%. Furthermore, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 44.14.
On December 08th, 2017, Radius Health announced data from two ongoing Phase-1 studies of RAD1901, an oral selective estrogen receptor degrader, in patients with estrogen receptor positive (ER+) breast cancer. As of the cut-off date of October 07th, 2016, 20 patients have been treated in the RAD1901 Phase IB safety expansion cohort at the 400 mg dose. These patients are heavily pretreated ER+, HER2-negative advanced breast cancer patients who have received a median of 3 prior lines of therapy. RAD1901 was well-tolerated with the most common adverse events being low grade nausea and dyspepsia. In the ongoing European Phase-I RAD1901 FES-PET trial, the first three-patients were enrolled at 400 mg as of the October 07th cut-off date and achieved a reduction in 18F-FES uptake ranging from 79%-91% at day 14 compared to baseline. One patient had a confirmed partial response by RECIST criteria. All three patients remained on study drug with mean duration of treatment of 5.64 cycles. Sign up for your complimentary research report on RDUS at:
Barcelona, Spain headquartered Grifols S.A.'s stock finished Thursday's session 0.83% higher at $16.96 with a total trading volume of 544,458 shares. The Company's shares have advanced 6.53% in the last one month, 14.51% over the previous three months, and 5.54% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.42% and 7.82%, respectively. Additionally, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 63.81.
On December 14th, 2017, Grifols announced that it entered into an agreement to acquire the Nucleic Acid Testing (NAT) donor screening unit from the US Company Hologic for a purchase price of USD$1.85 billion. This agreement encompasses research, development, and manufacture of assays and instruments activities using NAT technology that makes possible to detect the presence of infectious agents in blood and plasma donations, contributing to greater transfusion safety.
On January 03rd, 2017, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Register for free on Stock-Callers.com and download the latest research report on GRFS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All